These results align with our previous study (Jin et al., 2023), where we demonstrated that expression profiles of HPGD, PACS1, and TDP2 were consistent across cfRNAs and tissue samples, underscoring the potential of these genes as robust biomarkers for CRC [7]. This evidence concerns the gene TDP2 and colorectal carcinoma.